These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30351237)

  • 1. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
    Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
    Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical
    Kahaly GJ; Steiner L; van der Lee MMC; van Achterberg TAE; Arends RJ; Karstens WFJ; Weirauch T; Henseling J; Frommer L; Wolf J; George A
    Thyroid; 2023 Jun; 33(6):732-742. PubMed ID: 37016815
    [No Abstract]   [Full Text] [Related]  

  • 3. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
    Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
    J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
    Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
    J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.
    van Zeijl CJ; van Koppen CJ; Surovtseva OV; de Gooyer ME; Plate R; Conti P; Karstens WJ; Timmers M; Saeed P; Wiersinga WM; Miltenburg AM; Fliers E; Boelen A
    J Clin Endocrinol Metab; 2012 May; 97(5):E781-5. PubMed ID: 22419705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 9. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C; Morgenthaler NG
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.
    Mizutori Y; Chen CR; Latrofa F; McLachlan SM; Rapoport B
    J Clin Endocrinol Metab; 2009 Mar; 94(3):927-35. PubMed ID: 19066298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
    Smith TJ; Hegedüs L; Douglas RS
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin receptor antibodies and Graves' orbitopathy.
    Diana T; Ponto KA; Kahaly GJ
    J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.
    Sanders J; Evans M; Betterle C; Sanders P; Bhardwaja A; Young S; Roberts E; Wilmot J; Richards T; Kiddie A; Small K; Platt H; Summerhayes S; Harris R; Reeve M; Coco G; Zanchetta R; Chen S; Furmaniak J; Smith BR
    Thyroid; 2008 Jul; 18(7):735-46. PubMed ID: 18631002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
    Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
    Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
    [No Abstract]   [Full Text] [Related]  

  • 16. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.
    Neumann S; Pope A; Geras-Raaka E; Raaka BM; Bahn RS; Gershengorn MC
    Thyroid; 2012 Aug; 22(8):839-43. PubMed ID: 22784331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
    Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
    Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
    Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
    Kumar S; Coenen M; Iyer S; Bahn RS
    Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.